For peptide-based cancer vaccines to work, they need CD8+ epitopes to use the antigen cross-presentation pathway, which activates CTL anti-tumor immunity, and CD4+ epitopes to activate T-helper cells, which keeps the CTL effector function going [46]. The gene discussed is CD4; the disease is cancer.